Synaptobrevin Reporting Construct for Botulinum Neurotoxin Assay
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell-based assays for botulinum neurotoxins, particularly those that cleave synaptobrevin, face challenges in accurately characterizing botulinum serotype B neurotoxin due to interference from excessive persistence of fluorescent emission after proteolytic degradation.
Innovation Solution
The development of a pair of peptide constructs with co-localization sequences and detectable labels, where one member incorporates mutations to prevent or reduce botulinum B neurotoxin cleavage, allowing for data normalization and enhanced degradation of released fluorescent peptides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If a reporting construct with synaptobrevin-based moiety is used in cell-based assays for botulinum serotype B neurotoxin, then the assay sensitivity and specificity are improved, but excessive persistence of fluorescent emission after proteolytic degradation interferes with accurate measurement
Solution Approach 1:
The patent extracts and removes the persistent fluorescent signal from the system by designing the reporting construct to undergo complete proteolytic degradation. The synaptobrevin-based moiety is specifically engineered to be cleaved by botulinum neurotoxin, releasing the fluorescent peptide which then undergoes further degradation by cellular proteases, effectively removing the interfering persistent signal while maintaining the desired assay sensitivity.
Solution Approach 2:
The patent changes the temporal parameter of fluorescent emission by modifying the stability characteristics of the reporting construct. Through selective proteolysis at specific cleavage sites within the synaptobrevin sequence, the fluorescent signal transitions from a persistent state to a transient state, allowing accurate measurement of toxin activity without interference from prolonged fluorescence.
2Measurement precision
If synaptobrevin sequence is used as the proteolytic substrate, then botulinum serotype B neurotoxin activity can be detected, but the membrane spanning sub-domain causes N-terminal fluorophore to be positioned on the interior of the vesicle preventing energy transfer
Solution Approach 1:
The patent segments the synaptobrevin sequence into distinct functional domains: an N-terminal region containing the fluorophore and cleavage site, a central hydrophobic region corresponding to the membrane-spanning domain, and a C-terminal region. This segmentation allows the fluorophore to be positioned in the cytosol rather than embedded in the membrane, enabling proper FRET energy transfer while maintaining the integrity of the membrane-associated substrate for neurotoxin detection.
Solution Approach 2:
The patent introduces a linker or spacer sequence between the N-terminal fluorophore and the hydrophobic membrane-spanning region of synaptobrevin. This intermediary element acts as a flexible tether that positions the fluorophore in the appropriate spatial location for energy transfer while allowing the hydrophobic region to properly embed in the vesicle membrane, thus resolving the structural conflict.
3Object-generated harmful factors
If degron sequences are added to enhance degradation rate of released fluorescent peptides, then interference from undegraded fragments is reduced, but the construct design becomes more complex
Solution Approach 1:
The patent incorporates degron sequences directly into the design of the reporting construct before proteolytic cleavage occurs. These degradation-enhancing elements are pre-positioned at strategic locations within the construct, ensuring that once the neurotoxin cleaves the synaptobrevin substrate, the released fluorescent peptide fragments are immediately recognized and degraded by cellular protease systems, preventing interference with assay measurements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a highly sensitive and specific cell-based assay for botulinum serotype B neurotoxin, reducing interference from undegraded fragments and improving the dynamic range of the assay, thereby correlating well with animal-based testing.
Implementation Method 1
the first fluorescent peptide and the second fluorescent peptide (which can be derived from GFP or a GFP mutation) are positioned such that no useful (e.g. less than about 5%) Forster resonance energy transfer (FRET) occurs between them
Implementation Method 2
a first linking peptide derived from synaptobrevin positioned between the first membrane binding peptide and the first fluorescent peptide
Data Source
AI summary
Compositions and methods for improved cell-based methods of characterizing botulinum neurotoxins are provided. Cells utilized in these methods include a reporting construct that is cleaved following uptake and processing of botulinum neurotoxin by the cell, resulting in proteolysis of the portion of the reporting construct that is released following cleavage. The released portion includes a fluorophore and amino acid substitutions or sequences that enhance the rate of proteolysis. A pair of reporting constructs can be utilized in which one member of the pair is modified to resist cleavage by the botulinum neurotoxin while co-localizing with the remaining member of the pair.